Open or percutaneous revascularization for chronic splanchnic syndrome  by van Petersen, André S. et al.
EVIDENCE SUMMARY
Jan D. Blankensteijn, MD, PhD, Section Editor
Open or percutaneous revascularization for
chronic splanchnic syndrome
André S. van Petersen, MD, Jeroen J. Kolkman, MD, PhD, Roland J. Beuk, MD, PhD, Ad B. Huisman,
MD, PhD, Cees J. A. Doelman, PhD, and Robert H. Geelkerken, MD, PhD; for the Multidisciplinary
Study Group Of Splanchnic Ischemia, Enschede, The Netherlands
Background: Treatment of chronic splanchnic syndrome remains controversial. In the past 10 years, endovascular repair
(ER) has replaced open repair (OR) to some extent. This evidence summary reviews the available evidence for ER or OR
of chronic splanchnic syndrome.
Methods: A systematic literature search of MEDLINE database was performed to identify all studies that evaluated
treatment of chronic splanchnic syndrome between 1988 and 2009.
Results: The best available evidence consists of prospectively accumulated but retrospectively analyzed data with a high risk for
confounding. Only a few of these studies incorporated functional tests to assess splanchnic ischemia before or after treatment.
ER has the advantage of low short-term morbidity but the disadvantage of decreased long-term primary patency compared
with OR. ER and OR have similar rates of secondary patency, although the reintervention rate after ER is higher.
Conclusion: ER appears to be preferential in the treatment of elderly patients and in patients with comorbidity, severe
cachexia, or hostile abdomen. Long-term results after OR are excellent. OR can still be proposed as the preferred option
for relatively young and fit patients. ( J Vasc Surg 2010;51:1309-16.)Chronic splanchnic disease, defined as asymptomatic
obstruction of the splanchnic arteries, can be found in 18%
of individuals aged 65 years.1,2 Progression to acute or
chronic splanchnic syndrome (CSS), defined as symptom-
atic disease, occurs in about 5% of patients with chronic
splanchnic disease3 and in 27% in patients with two- and
three-vessel disease.3,4 A functional test for mucosal perfu-
sion is mandated to differentiate between chronic splanch-
nic disease and CSS.5-7 The most common cause of CSS is
atherosclerotic intraluminal osteal stenoses.8,9 Intraluminal
stenoses must be differentiated from extraluminal stenoses,
which is mostly caused by compression of the celiac artery
by the arcuate ligament.10 Isolated endovascular treatment
in these patients is contraindicated without foregoing ap-
propriate cleavage of the arcuate ligament.11-15
For many decades, the broad consensus was that timely
diagnosis and appropriate revascularization diminished the
high mortality of acute splanchnic syndrome and in case of
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doi:10.1016/j.jvs.2009.12.064CSS, could durably restore the symptoms. Classic transab-
dominal open repair (OR) has been the standard treatment
since 195816 but has the burden of major abdominal vas-
cular surgery. Percutaneous endovascular repair (ER) has
been a minimally invasive alternative for treatment of CSS
since the first splanchnic artery angioplasty in 1980.17
This article summarizes the existing level of evidence of
OR and ER treatment for CSS caused by atherosclerotic
stenoses of the splanchnic arteries.
METHODS
A systematic literature search of the MEDLINE data-
base was performed to identify all studies that evaluated
treatment of CSS between 1988 and 2009. Study designs
included for review were randomized controlled trials
(RCTs), observational studies, and meta-analyses. Studies
with 10 patients were excluded. Technical success, pri-
mary patency, secondary patency, and clinical patency were
defined according to the reporting standards.18 Studies
were analyzed by level of evidence (www.cebm.net).
Weighted averages of results from OR and ER were com-
pared using the 2 test.
RESULTS
Studies comparing clinical and anatomic outcome
of OR and ER. Only eight studies19-26 comparing OR
with ER could be identified. Outcomes of OR and ER are
summarized in Table I, A, B and C. All were retrospectively
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bias, such as differences in stenotic and occluded vessels,
location of stenosis (ostial vs nonostial), number of treated
vessels, percutaneous transluminal angioplasty (PTA) or
stent, type of stent, access, type of anticoagulant therapy,
and comorbidity. None of these studies incorporated
functional tests before or after treatment.6 Inclusion on
intention-to-treat basis, numbers lost to follow-up, assess-
ment of clinical success or anatomic patency were all not
Table I, A. Studies comparing outcome of open repair (O
syndrome
Author, year Study period
Davies,21 2009 1996-2006
Oderich,26 2009 1991-2005
Zerbib,24 2008 2000-2006
Atkins,19 20007 1991-2005
Biebl,23 2007 1994-2003
Sivamurthy,22 2006 1989-2003
Brown,25 2005 2001-2004
Kasirajan,20 2001 1995-1998
Summation
Table I, B. Studies comparing outcome of open repair (O
syndrome
Revascularized vessels per
patient, No.
Patients with technical
success, %
OR ER P OR ER P
1.5 1.2 NA 100 93 NA
1.4 1.0 .01 100 93 NA
1.8 1.3 .01 NA 95 NA
1.8 1.4 .001 100 97 NA
1.8 1.3 NA NA 93 NA
1.7 1.3 .001 NA NA NA
1.7 1.2 NA 100 95 NA
1.5 1.1 NA NA NA NA
1.7 1.2 .0001 100 95 NS
ICU, Intensive care unit; NA, not applicable; NS, not significant.
Table I, C. Studies comparing outcome of open repair (O
syndrome
FU, mo
Patients lost to
FU, %
OR ER P OR ER O
34 34 NS NA NA N
36 30 .05 NA NA 6
21 15 .28 0 0 N
42 15 NA NA NA 6
25 10 .07 0 0 8
25 19 NA NA NA N
34 13 NA NA 7 N
60 24 NA 0 0 6
35 20 6
FU, Follow-up; NA, not applicable; NS, not significant.recorded unambiguously.The short-term main outcome parameters were gen-
erally similar, although the in-hospital morbidity was
better after ER, and the intensive care unit and hospital
lengths of stay were shorter. Long-term primary ana-
tomic patency and clinical outcome were better after
OR. With significantly more and mainly endovascular
reinterventions in the ER group, secondary patency was
not significantly different between ER and OR. The data
presented in Table IA and B represent outcomes of
nd endovascular repair (ER) of chronic splanchnic
Level of evidence
Patients, No.
OR ER
2c 17 15
2b 146 83
2c 15 14
2b 49 31
2c 26 23
2c 41 19
2c 33 14
2c 85 28
412 227
nd endovascular repair (ER) of chronic splanchnic
Patients with immediate
pain relief, %
Patients with major in-hospital
30-day morbidity, %
OR ER P OR ER P
100 86 NA 35 7 .09
NA NA NA 20 7 NA
98 95 NA 36 11 0
90 87 NA 4 13 14
NA 100 NA 33 0 .01
100 100 .19 42 4 .02
71 33 .01 46 19 .01
NA NA NA 33 18 .12
93 88 NS 32 11 .0001
nd endovascular repair (ER) of chronic splanchnic
ents with appropriate
radiologic FU, %
Patients with recurrent
stenoses, %
ER P OR ER P
NA NA NA NA NA
47 NA 7 37 .0001
NA NA 0 21 .09
59 NA 37 32 .65
26 NA 8 25 .003
NA NA 0 39 .0002
NA NA NA 57 NA
68 NA 24 27 .62
51 .0067 15 37 .0001R) aR) aR) a
Pati
R
A
0
A
5
8
A
A
4
4centers of excellence.
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who underwent OR for CSS, in-hospital mortality was
14.7%, the complication rate was 44.6%, and the median
hospital stay was 14 days. ORmortality increased up to 20%
in patients with comorbidity and even to 48% in patients
with renal insufficiency.27 In patients undergoing major
intra-abdominal surgery, significant weight loss (body mass
index 19.5 kg/m2) was associated with twofold to ten-
Table I, A. Continued
Diseased vessels per patient, No. Occlusions of all
OR ER P OR ER
2.2 1.9 .26 NA NA
2.5 2.6 NA 36 27
2.4 2.2 NA NA NA
2.5 2.3 .18 49 38
2.7 2.2 NA NA NA
1.9 1.5 .03 NA NA
NA NA NA NA NA
2.5 2.5 .71 57 36
2.4 2.3 NA 45 31
Table I, B. Continued
Patients with in-hospital
30-day mortality, % Hospital stay, days
OR ER P OR ER P
5.9 0.0 .999 14.2 4 .0003
0.0 14.3 .22 22 20 .0160
2.7 2.4 NS 12 3 .0001
2.0 3.2 .74 12 4 .0010
9.0 0.0 .25 10 2 .01
7.7 0.0 .52 12 1 .001
15.0 21.0 .08 23 1 .0003
8.2 10.7 .71 13 5 .0800
6 5 NS 15 5
Table I, C. Continued
Patients with recurrent
symptoms, %
Patients with
reinterventions, %
Primar
v
OR ER P OR ER P OR E
29 13 NA NA NA NA 83 5
5 31 .001 5 31 .0001 88 4
7 21 .33 0 0 NA 70 5
22 23 .98 22 16 .49 90 5
0 9 .04 0 13 .01 NA 7
35 71 .01 12 5 NA 83 6
NA NA NA NA 53 NA NA 2
12 39 .001 NA 4 NA NA N
13 30 .0001 9 20 .0004 86 5fold increased major morbidity and death.28-31 One pro-spective study including CSS patients unfit for OR demon-
strated that patients benefit from ER in80% of cases, with
an acceptable complication rate and without procedurally
or CSS-related death.32 A recent article from Schermer-
horn et al33 showed a significantly lower mortality rate of
3.7% after ER compared with 13% after OR.
The limitation of ER is that antegrade recanalization of
lengthy or heavy calcified osteal occlusions was not feasible.
ed vessels, % Occlusions of all treated vessels, %
P OR ER P
NA 62 11 .0024
.027 NA NA NA
NA NA 0 NA
NS NA 0 NA
NA 72 17 .0003
NA NA 0 NA
NA NA NA NA
.0544 48 3 .0001
.0001 55 6 .0001
Patients in ICU, % ICU stay, days
R ER P OR ER P
6 0 .0001 4.4 0 .0001
A NA NA NA NA NA
A NA NA 0.7 4.6 .0001
A NA NA 7.3 0.3 .002
A 0 NA 3 0 .01
A NA NA NA NA NA
3 14 .0001 15 6 0.46
A NA NA NA NA NA
8 6 .0001 6 2
ncy, %
Secondary
patency,
% vessels
Clinical patency, %
patients
P OR ER P OR ER P
.11 100 65 .0061 100 73 .014
.00001 97 88 .005 96 92 NS
.17 NA NA NA 93 71 .1
.001 69 87 .003 83 61 .02
NA NA NA NA 89 75 NA
.23 NA NA NA 59 20 .0004
NA NA NA NA NA 93 NA
NA 76 73 .62 87 66 .001
.0001 87 83 NS 88% 74 .0001diseasO
7
N
N
N
N
N
9
N
8y pate
essels
R
4
1
8
8
5
8
7
A
1Retrograde ER of splanchnic artery ostia is a minimally
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Retrograde ER through collaterals of the celiac artery was
described in one patient.37
Only two OR series30,38 reported appropriately deter-
mined primary anatomic patency calculated by life-table
methods of up to 93% at 36 months and 89% at 72 months.
Only one ER series,39 characterized by at least 25% incom-
plete follow-up, reported a primary patency of 64% at 36
months. Primary patency was defined as a combination of
freedom of symptoms and freedom of restenoses.
Clinical and anatomic outcome of uncontrolled
studies. Almost all studies, including those with multives-
sel CSS patients treated with OR, supported the statement
that long-term relief of symptoms can be achieved best by
repair of more than one splanchnic artery.28,38,40-42 The
results of the uncontrolled ER series are summarized in
Table II. In the ER series, the concept of preferable mul-
tivessel revascularization was both supported22,39,46 and
rejected,29,58 albeit with a high risk of confounding.
Weighted averages showed a slight advantage for long-term
pain relief in patients treated with multivessel ER vs OR.
Our analysis of all uncontrolled ER series showed no
Table II. Noncomparative studies of endovascular repair
Author, year
Study
period
Level of
evidence
Patients
included
No.
Peck,39 2009 2002-2008 2b 49
Fioole,43 2009 2001-2008 2c 51
Davies,21 2009 1996-2006 2c 15
Oderich,26 2009 1991-2005 2a 83
Sarac,44 2008 2001-2005 2b 65
Zerbib,24 2008 2000-2006 2c 14
Heiss,45 2008 1999-2005 2b 17
Biebl,23 2007 1994-2003 2c 23
Atkins,19 2007 1991-2005 2a 31
Schaefer,56 2006 2000-2005 2b 19
Silva,46 2006 1993-2004 2b 59
Sivamurthy,22 2006 1989-2003 2c 19
Brown,25 2005 2000-2004 2c 14
Landis,47 2005 1986-2003 2c 29
van Wanroij,32 2004 1996-2002 2b 27
Chahid,48 2004 1988-2002 2b 14
AbuRahma,49 2003 4.5 year 2c 22
Sharafuddin,50 2003 1999-2002 2b 25
Steinmetz,51 2002 1989-2001 2c 19
Matsumoto,11 2002 1981-1999 2b 33
Kasirajan,20 2001 1995-1998 2c 28
Sheeran,52 1999 1993-1998 2c 12
Maspes,53 1998 1982-1995 2c 23
Allen,54 1996 1984-1994 2c 19
Hallisey,55 1995 1980-1994 2c 16
Odurny,57 1988 1980-1987 2c 10
28
Summation
Vessels revascularized, No.
1.4 artery 142
1.1 artery 147
Pa
FU, Follow-up; NA, not applicable; NS, not significant.
a2 test.significant differences between PTA alone and stenting.The following algorithm is a comprehensive summary of
the opinions about PTA and stenting. Additional stenting
after PTA should be performed in case of (1) unsatisfactory
anatomic outcome, preferably quantified as a residual ste-
noses of 30% or a residual pressure gradient of 15 mm
Hg, (2) early recurrent stenoses (12 months), and (3)
calcified ostial or high-grade eccentric stenoses, chronic
occlusions, or dissections.11,47
Complications related to ER. Complications related
to ER are reported in Table III. Most complications are
access-site related. Because of the high percentages of com-
plications after brachial approach,19,21,32,39,45,46,48,49,59
the iliofemoral artery is the preferred access site.
Splanchnic artery occlusions were successfully treated
by ER in 73 of 74 vessels.20,21,23,25,39,43,44,46,47,50,52,55
The 1-year Kaplan-Meier cumulative primary patency rates
were similar: 63% (95% confidence interval [CI], 45%-81%)
vs 70% (95% CI, 43%-96%).44 ER of occluded splanchnic
arteries was clearly challenging, however, and may result in
a higher incidence of complications.
Untreated or underestimated dissections have the po-
tential to result in acute splanchnic syndrome. Eight of 26
ronic splanchnic syndrome
Diseased
vessels per
atient, No.
Revascularized
vessels per
patient, No.
Patients with
technical
success, %
Patients with
immediate
pain relief, %
2.0 1.3 88 90
NA 1.2 93 78
1.9 1.2 93 86
2.6 1.3 95 95
NA 1.3 100 85
2.2 1.0 93 NA
2.2 1.2 91 81
NA 1.3 NA 100
2.3 1.4 97 87
NA 1.2 96 96
2.4 1.3 97 88
1.5 1.2 95 33
NA 1.3 93 100
NA 1.4 97 90
1.5 1.1 93 67
2.0 1.2 86 100
2.0 1.1 96 95
2.0 1.0 96 88
1.9 1.0 100 94
NA 1.4 88 88
NA 1.1 NA NA
2.0 1.1 92 89
1.8 1.6 90 77
NA 1.3 95 79
2.6 1.6 88 88
2.1 1.9 80 80
2.1 1.3 93 86
2.2 1.5 91 86
1.9 1.1 95 85
NS NSof ch
,
preports21,45,47,51,54,57 described dissections in 11 of 736
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patients died, and eight reinterventions were performed, of
which five were OR (Table III).
Another rare complication is peripheral embolism.
Six symptomatic splanchnic embolic events were docu-
mented in case reports.20,38,44,60 The consequences
were acute splanchnic syndrome adding to in-hospital
deaths. If a clinically significant embolic event occurs,
aspiration or thrombolytic techniques can be used. Only
one study mentioned the routine use of a protection
device.25
DISCUSSION
The evidence for OR or ER in case of splanchnic artery
atherosclerotic obstructive disease is still merely based on
the preference and experience of the individual interven-
tionalist. Properly designed and well-executed studies are
scarce. Consequently, the best available level of evidence is
2b. Ideally, a randomized study determines the position of
OR and ER. Because of the low number of patients poten-
tially suitable for both techniques, a large multinational
Table II. Continued
Patients with
major
morbidity, %
In-hospital
mortality, %
FU,
mo
Patients with
appropriate
radiologic FU, %
Patie
recu
symp
17 2 37 76
4 0 25 NA
7 0 34 NA
11 2 30 47
5 8 12 100 N
7 14 15 NA
12 6 26 65
4 0 10 26
13 3 15 65
NA 11 17 100
0 0 38 88
19 21 19 NA
0 0 13 NA
3 7 28 NA
11 0 19 100
0 0 29 50
0 0 26 NA
12 0 15 72
11 0 31 84
0 0 38 52
18 11 27 68
0 8 16 22
0 0 27 9
5 5 39 22
NA 6 28 19
NA 10 17 NA
7 4 25 59
4 4 25.5 40
10 4 21.3 76
NS NS .0001 Nrandomized trial would be required, which may be impos-sible to organize. Until then, a balanced decision must be
made between a minimally invasive procedure with low
morbidity and more endovascular reinterventions vs an
open procedure with higher morbidity and better primary
patency rates.
CONCLUSION
On the basis of this review, endovascular repair is
recommended in patients with limited life expectancy, high
cardiopulmonary risk, cachexia, or hostile abdomen. Open
repair is the preferred option for patients who are relatively
young, with age50 years as a guideline, and otherwise fit
for surgical repair.
REFERENCES
1. Roobottom CA, Dubbins PA. Significant disease of the celiac and
superior mesenteric arteries in asymptomatic patients: predictive
value of Doppler sonography. AJR Am J Roentgenol 1993;161:
985-8.
2. Hansen KJ, Wilson DB, Craven TE, Pearce JD, English WP, Edwards
MS, et al. Mesenteric artery disease in the elderly. J Vasc Surg 2004;40:
th
%
Patients with
restenosis, %
Patients with
reinterventions, %
Patients with long-term
pain relief and
reinterventions incl, %
65 29 95
30 13 78
NA NA 73
37 31 92
NA 11 75
21 0 71
15 23 94
25 13 75
32 16 61
21 11 78
29 17 83
39 5 20
57 53 NA
NA 34 88
19 19 81
29 29 79
32 19 61
12 8 80
31 20 94
17 18 97
27 4 66
NA 22 78
13 13 100
20 11 79
NA 25 94
40 30 75
29 19 79%
25 22 86
23 12 75
NS .0514 .0346nts wi
rrent
toms,
29
33
13
31
A
21
31
9
23
26
17
71
50
34
23
21
32
8
19
17
39
22
13
16
25
50
27
25
24
S45-52.
.JOURNAL OF VASCULAR SURGERY
May 20101314 van Petersen et al3. Thomas JH, Blake K, Pierce GE, Hermreck AS, Seigel E. The clinical
course of asymptomatic mesenteric arterial stenosis. J Vasc Surg 1998;
27:840-4.
4. Connolly JE, Kwaan JH. Prophylactic revascularization of the gut. Ann
Surg 1979;190:514-22.
5. Kolkman JJ, Groeneveld AB, van der Berg FG, Rauwerda JA, Meuwis-
sen SG. Increased gastric PCO2 during exercise is indicative of gastric
ischaemia: a tonometric study. Gut 1999;44:163-7.
6. Otte JA, Geelkerken RH, Oostveen E, Mensink PB, Huisman AB,
Kolkman JJ. Clinical impact of gastric exercise tonometry on diagnosis
and management of chronic gastrointestinal ischemia. Clin Gastroen-
terol Hepatol 2005;3:660-6.
7. Mensink PB, Geelkerken RH, Huisman AB, Kuipers EJ, Kolkman JJ.
Twenty-four hour tonometry in patients suspected of chronic gastroin-
testinal ischemia. Dig Dis Sci 2008;53:133-9.
8. Bradbury AW, Brittenden J, McBride K, Ruckley CV. Mesenteric
ischaemia: a multidisciplinary approach. Br J Surg 1995;82:1446-59.
9. Taylor LM Jr, Moneta GL, Porter JM. Treatment of chronic visceral
ischemia. In: Rutherford RB, editor. Vacular surgery. Philadelphia:
Saunders; 2009. p. 1532-41.
10. van Petersen AS, Vriens BH, Huisman AB, Kolkman JJ, Geelkerken
RH. Retroperitoneal endoscopic release in the management of celiac
artery compression syndrome. J Vasc Surg 2009;50:140-7.
11. Matsumoto AH, Angle JF, Spinosa DJ, Hagspiel KD, Cage DL, Leung
DA, et al. Percutaneous transluminal angioplasty and stenting in the
treatment of chronic mesenteric ischemia: results and longterm
follow-up. J Am Coll Surg 2002;194(1 suppl):S22-31.
12. Matsumoto AH, Tegtmeyer CJ, Fitzcharles EK, Selby JB Jr, Tribble
CG, Angle JF, et al. Percutaneous transluminal angioplasty of visceral
arterial stenoses: results and long-term clinical follow-up. J Vasc Interv
Radiol 1995;6:165-74.
13. Delis KT, Gloviczki P, Altuwaijri M, McKusick MA. Median
Table III. Overview of procedure-related complications o
Author
Study
period
Level of
evidence
Patients
included,
No.
Revascula
vessels p
patient,
Peck39 2002-2008 2b 49 1.3
Fioole43 2001-2008 2c 51 1.2
Davies21 1996-2006 2c 15 1.2
Oderich26 1991-2005 2a 83 1.3
Sarac44 2001-2005 2b 65 1.3
Zerbib24 2000-2006 2c 14 1.0
Heiss45 1999-2005 2b 17 1.2
Biebl23 1994-2003 2c 23 1.3
Atkins19 1991-2005 2a 31 1.3
Schaefer56 2000-2005 2b 19 1.2
Silva46 1993-2004 2b 59 1.3
Sivamurthy22 1989-2003 2c 19 1.1
Brown25 2000-2004 2c 14 1.3
Landis47 1986-2003 2c 29 1.1
van Wanroij32 1996-2002 2b 27 1.1
Chahid48 1988-2002 2b 14 1.2
AbuRahma49 NA 2c 22 1.1
Sharafuddin50 1999-2002 2b 25 1.0
Steinmetz51 1989-2001 2c 19 1.0
Matsumoto11 1981-1999 2b 33 1.4
Kasirajan20 1995-1998 2c 28 1.1
Sheeran52 1993-1998 2c 12 1.1
Maspes53 1982-1995 2c 23 1.6
Allen54 1984-1994 2c 19 1.3
Hallisey55 1980-1994 2c 16 1.6
Odurny57 1980-1987 2c 10 1.9
Summation
No. (%) 736 1.3
CVA, Cerebrovascular accident; NA, not applicable; PSA, pseudoaneurysmarcuate ligament syndrome: open celiac artery reconstruction andligament division after endovascular failure. J Vasc Surg
2007;46:799-802.
14. Saddekni S, Sniderman KW, Hilton S, Sos TA. Percutaneous translu-
minal angioplasty of nonatherosclerotic lesions. AJR Am J Roentgenol
1980;135:975-82.
15. Cina CS, Safar H. Successful treatment of recurrent celiac axis
compression syndrome. A case report. Panminerva Med 2002;44:
69-72.
16. Shaw RS, Maynard EP 3rd. Acute and chronic thrombosis of the
mesenteric arteries associated with malabsorption; a report of two cases
successfully treated by thromboendarterectomy. N Engl J Med 1958;
258:874-8.
17. Furrer J, Gruntzig A, Kugelmeier J, Goebel N. Treatment of abdominal
angina with percutaneous dilatation of an arteria mesenterica superior
stenosis. Preliminary communication. Cardiovasc Intervent Radiol 1980;
3:43-4.
18. Rutherford RB, Baker JD, Ernst C, Johnston KW, Porter JM, Ahn S, et
al. Recommended standards for reports dealing with lower extremity
ischemia: revised version. J Vasc Surg 1997;26:517-38.
19. Atkins MD, Kwolek CJ, LaMuraglia GM, Brewster DC, Chung TK,
Cambria RP. Surgical revascularization versus endovascular therapy for
chronic mesenteric ischemia: a comparative experience. J Vasc Surg
2007;45:1162-71.
20. Kasirajan K, O’Hara PJ, Gray BH, Hertzer NR, Clair DG, Greenberg
RK, et al. Chronic mesenteric ischemia: open surgery versus percutane-
ous angioplasty and stenting. J Vasc Surg 2001;33:63-71.
21. Davies RS, Wall ML, Silverman SH, Simms MH, Vohra RK, Bradbury
AW, et al. Surgical versus endovascular reconstruction for chronic
mesenteric ischemia: a contemporary UK series. Vasc Endovascular
Surg 2009;43:157-64.
22. Sivamurthy N, Rhodes JM, Lee D, Waldman DL, Green RM, Davies
ovascular repair of chronic splanchnic syndrome
Patients with
brachial
approach, %
Patients with
treated stent, %
Occlusions of
all vessels
treated, %
Hematomas,
No.
86 89 21
20 100 3 3
NA 40 11
13 72 NA
70 100 28
NA 79 0 2
6 100 0
NA 96 17
90 87 0
30 100 0
23 100 5
0 90 0
100 100 2
19 31 33
100 89 0 1
21 43 0 1
NA 100 0
25 100 12
53 37 NA
87 36 0 2
61 82 3
15 100 23
39 0 0 1
48 0 0 1
44 0 4
10 0 0
44 8 11 (1.5)f end
rized
er
No.MG. Endovascular versus openmesenteric revascularization: immediate
JOURNAL OF VASCULAR SURGERY
Volume 51, Number 5 van Petersen et al 1315benefits do not equate with short-term functional outcomes. J Am Coll
Surg 2006;202:859-67.
23. Biebl M, Oldenburg WA, Paz-Fumagalli R, McKinney JM, Hakaim
AG. Surgical and interventional visceral revascularization for the treat-
ment of chronic mesenteric ischemia—when to prefer which? World
J Surg 2007;31:562-8.
24. Zerbib P, Lebuffe G, Sergent-Baudson G, Chamatan A, Massouille D,
Lions C, et al. Endovascular versus open revascularization for chronic
mesenteric ischemia: a comparative study. Langenbecks Arch Surg
2008;393:865-70.
25. Brown DJ, Schermerhorn ML, Powell RJ, Fillinger MF, Rzucidlo EM,
Walsh DB, et al. Mesenteric stenting for chronic mesenteric ischemia. J
Vasc Surg 2005;42:268-74.
26. Oderich GS, Malgor RD, Ricotta JJ 2nd. Open and endovascular
revascularization for chronic mesenteric ischemia: tabular review of the
literature. Ann Vasc Surg 2009;23:700-12.
27. Derrow AE, Seeger JM, Dame DA, Carter RL, Ozaki CK, Flynn TC, et
al. The outcome in the United States after thoracoabdominal aortic
aneurysm repair, renal artery bypass, and mesenteric revascularization. J
Vasc Surg 2001;34:54-61.
28. Cho JS, Carr JA, Jacobsen G, Shepard AD, Nypaver TJ, Reddy DJ.
Long-term outcome after mesenteric artery reconstruction: a 37-year
experience. J Vasc Surg 2002;35:453-60.
29. Park WM, Cherry KJ Jr, Chua HK, Clark RC, Jenkins G, Harmsen WS,
et al. Current results of open revascularization for chronic mesenteric
ischemia: a standard for comparison. J Vasc Surg 2002;35:853-9.
30. Kihara TK, Blebea J, Anderson KM, Friedman D, Atnip RG. Risk
factors and outcomes following revascularization for chronic mesenteric
ischemia. Ann Vasc Surg 1999;13:37-44.
31. Sungurtekin H, Sungurtekin U, Balci C, Zencir M, Erdem E. The
influence of nutritional status on complications after major intraab-
Table III. Continued
Thromboses,
No.
PSAs,
No.
Brachial
dissections,
No.
Splanchnic
dissections,
No.
Splanchnic
emboli,
No.
3 3
1 1
1
2 2 4
1
5
3
2 2
1
1
2
2 1
3
1
1
15 (2.0) 12 (1.6) 1 (0.1) 11 (11.5) 3 (0.4)dominal surgery. J Am Coll Nutr 2004;23:227-32.32. van Wanroij JL, van Petersen AS, Huisman AB, Mensink PB, Gerrits
DG, Kolkman JJ, et al. Endovascular treatment of chronic splanchnic
syndrome. Eur J Vasc Endovasc Surg 2004;28:193-200.
33. SchermerhornML, Giles KA, Hamdan AD,Wyers MC, Pomposelli FB.
Mesenteric revascularization: management and outcomes in the United
States, 1988-2006. J Vasc Surg 2009;50:341-8.
34. Wyers MC, Powell RJ, Nolan BW, Cronenwett JL. Retrograde mesen-
teric stenting during laparotomy for acute occlusive mesenteric isch-
emia. J Vasc Surg 2007;45:269-75.
35. Moyes LH,McCarter DH, Vass DG, Orr DJ. Intraoperative retrograde
mesenteric angioplasty for acute occlusive mesenteric ischaemia: a case
series. Eur J Vasc Endovasc Surg 2008;36:203-6.
36. Sonesson B, Hinchliffe RJ, Dias NV, Resch TA, Malina M, Ivancev K.
Hybrid recanalization of superior mesenteric artery occlusion in acute
mesenteric ischemia. J Endovasc Ther 2008;15:129-32.
37. Robken J, Shammas NW. Treatment of a totally occluded superior
mesenteric artery facilitated by retrograde crossing via collaterals from
the celiac artery. J Endovasc Ther 2007;14:745-7.
38. McMillan WD, McCarthy WJ, Bresticker MR, Pearce WH, Schneider
JR, Golan JF, et al. Mesenteric artery bypass: objective patency deter-
mination. J Vasc Surg 1995;21:729-40.
39. Peck MA, Conrad MF, Kwolek CJ, LaMuraglia GM, Paruchuri V,
Cambria RP. Intermediate-term outcomes of endovascular treatment
for symptomatic chronic mesenteric ischemia. J Vasc Surg 2010;51:
140-7.e2.
40. McAfee MK, Cherry KJ Jr, Naessens JM, Pairolero PC, Hallett JW Jr,
Gloviczki P, et al. Influence of complete revascularization on chronic
mesenteric ischemia. Am J Surg 1992;164:220-4.
41. Hollier LH, Bernatz PE, Pairolero PC, Payne WS, Osmundson PJ.
Surgical management of chronic intestinal ischemia: a reappraisal. Sur-
nt dislodgement
or release
problems, No.
CVAs,
No.
Renal
insufficiency,
No.
Procedurally related
complications,
No (%)
2 1 9 (18.4)
5 (9.8)
1 2 (13.3)
4 12 (14.5)
10 (15.4)
2 (14.3)
1 2 (11.8)
0 (0.0)
1 2 8 (25.8)
3 (15.8)
1 5 (8.5)
0 (0.0)
0 (0.0)
1 (3.4)
2 3 (11.1)
2 (14.3)
0 (0.0)
1 3 (12.0)
3 (15.8)
5 (15.2)
0 (0.0)
0 (0.0)
1 (4.3)
2 (10.5)
1 1 (6.3)
1 (10.0)
9 (1.2) 3 (0.4) 5 (0.7) 80 (10.9)Stegery 1981;90:940-6.
JOURNAL OF VASCULAR SURGERY
May 20101316 van Petersen et al42. Geelkerken RH, van Bockel JH, de Roos WK, Hermans J, Terpstra JL.
Chronic mesenteric vascular syndrome. Results of reconstructive sur-
gery. Arch Surg 1991;126:1101-6.
43. Fioole B, van de Rest HJ, Meijer JR, van LeersumM, van Koeverden S,
Moll FL, et al. Percutaneous transluminal angioplasty and stenting as
first-choice treatment in patients with chronic mesenteric ischemia. J
Vasc Surg 2010 [E-pub ahead of print: doi:10.1016/j.jvs.2009.
08.055].
44. Sarac TP, Altinel O, Kashyap V, Bena J, Lyden S, Sruvastava S, et al.
Endovascular treatment of stenotic and occluded visceral arteries for
chronic mesenteric ischemia. J Vasc Surg 2008;47:485-91.
45. Heiss P, Zorger N, Kaempfe I, Jung EM, Pfister K, Paetzel C, et al.
[Stenting in the treatment of chronic mesenteric ischemia: technical and
clinical success rates]. Rofo 2008;180:906-14.
46. Silva JA, White CJ, Collins TJ, Jenkins JS, Andry ME, Reilly JP, et al.
Endovascular therapy for chronic mesenteric ischemia. J Am Coll
Cardiol 2006;47:944-50.
47. Landis MS, Rajan DK, Simons ME, Hayeems EB, Kachura JR, Snider-
man KW. Percutaneous management of chronic mesenteric ischemia:
outcomes after intervention. J Vasc Interv Radiol 2005;16:1319-25.
48. Chahid T, Alfidja AT, Biard M, Ravel A, Garcier JM, Boyer L. Endo-
vascular treatment of chronicmesenteric ischemia: results in 14 patients.
Cardiovasc Intervent Radiol 2004;27:637-42.
49. AbuRahma AF, Stone PA, Bates MC, Welch CA. Angioplasty/stenting
of the superior mesenteric artery and celiac trunk: early and late out-
comes. J Endovasc Ther 2003;10:1046-53.
50. Sharafuddin MJ, Olson CH, Sun S, Kresowik TF, Corson JD. Endo-
vascular treatment of celiac and mesenteric arteries stenoses: applica-
tions and results. J Vasc Surg 2003;38:692-8.
51. Steinmetz E, Tatou E, Favier-Blavoux C, Bouchot O, Cognet F,
Cercueil JP, et al. Endovascular treatment as first choice in chronic
intestinal ischemia. Ann Vasc Surg 2002;16:693-9.52. Sheeran SR, Murphy TP, Khwaja A, Sussman SK, Hallisey MJ. Stent
placement for treatment of mesenteric artery stenoses or occlusions. J
Vasc Interv Radiol 1999;10:861-7.
53. Maspes F, Mazzetti di Pietralata G, Gandini R, Innocenzi L, Lupattelli
L, Barzi F, et al. Percutaneous transluminal angioplasty in the treatment
of chronic mesenteric ischemia: results and 3 years of follow-up in 23
patients. Abdom Imaging 1998;23:358-63.
54. Allen RC, Martin GH, Rees CR, Rivera FJ, Talkington CM, Garrett
WV, et al. Mesenteric angioplasty in the treatment of chronic intestinal
ischemia. J Vasc Surg 1996;24:415-21.
55. Hallisey MJ, Deschaine J, Illescas FF, Sussman SK, Vine HS, Ohki SK,
et al. Angioplasty for the treatment of visceral ischemia. J Vasc Interv
Radiol 1995;6:785-91.
56. Schaefer PJ, Schaefer FK, Hinrichsen H, Jahnke T, Charalambous N,
Heller M, et al. Stent placement with the monorail technique for
treatment of mesenteric artery stenosis. J Vasc Interv Radiol 2006;17:
637-43.
57. Odurny A, Sniderman KW, Colapinto RF. Intestinal angina: percuta-
neous transluminal angioplasty of the celiac and superior mesenteric
arteries. Radiology 1988;167:59-62.
58. Foley MI, Moneta GL, Abou-Zamzam AMJ, Edwards JM, Taylor
LM Jr, Yeager RA, et al. Revascularization of the superior mesenteric
artery alone for treatment of intestinal ischemia. J Vasc Surg 2000;
32:37-47.
59. Alvarez-Tostado JA, Moise MA, Bena JF, Pavkov ML, Greenberg RK,
Clair DG, et al. The brachial artery: a critical access for endovascular
procedures. J Vasc Surg 2009;49:378-85.
60. Rose SC, Quigley TM, Raker EJ. Revascularization for chronic mesen-
teric ischemia: comparison of operative arterial bypass grafting and
percutaneous transluminal angioplasty. J Vasc Interv Radiol 1995;6:
339-49.Submitted Sep 15, 2009; accepted Dec 23, 2009.
